-- 长春高新技术产业股份有限公司（深交所代码：000661）旗下子公司长春基因医药股份有限公司的GenSci155注射液临床试验申请已获中国监管机构批准。 根据周四提交给深圳证券交易所的文件，该药物适用于预防早产儿支气管肺发育不良和治疗急性缺血性脑卒中。
Related Articles
Asia
ScinoPharm Taiwan Logs NT$16.5 Million Profit in Q1
ScinoPharm Taiwan (TPE:1789) posted a profit attributable to owners of NT$16.5 million, or NT$0.02 per share, in the first quarter of the year, according to a Wednesday Taiwan bourse filing.Shares slid over 2% in Thursday's midday trade.Operating revenue stood at NT$659.7 million, the pharmaceutical company said.The company did not provide comparative year-ago figures.
$TPE:1789
Asia
Kina Securities Lists Papua New Guinea's First Wholesale Corporate Bond
Kina Securities' (ASX:KSL) 235 million Papua New Guinean Kina, 10-year unsecured subordinated wholesale corporate bond was listed on PNGX Markets, the operator of Papua New Guinea's national stock exchange, on Wednesday, according to a Thursday Australian bourse filing.This represents Papua New Guinea's first listed wholesale corporate bond.The firm expects the issuance to support its balance sheet strength, capital management objectives, and the growth of its banking and financial services operations.Its shares rose 1% in recent trading on Thursday.
$ASX:KSL
Asia
Home First Q4 Profit Soars to INR 1.5 Billion, Beats Estimates
Home First Finance Company India's (NSE:HOMEFIRST, BOM:543259) profit after tax rose to 1.49 billion Indian rupees in the fiscal fourth quarter ended March 31, from 1.05 billion rupees a year ago.Earnings per share came in at 14.22 rupees from 11.45 rupees a year ago, the financial services provider said in a filing to the Indian stock exchanges on Wednesday. The EPS was higher than the 14.08 rupees estimated by the analysts polled by Visible Alpha.Total revenue from operations also increased to 5.01 billion rupees from 2.15 billion rupees a year ago.The company's board recommended a dividend of 5.20 rupees per share of a face value of 2 rupees each for the financial year ended March 31.The company's shares were down 2% in recent trade.
$BOM:543259$NSE:HOMEFIRST